FitzGerald dynasty

Rebellion Defense Appoints Ben FitzGerald as CEO

Retrieved on: 
Monday, December 18, 2023

Rebellion Defense is thrilled to announce the appointment of Executive Chair Ben FitzGerald as its new Chief Executive Officer (CEO), effective 1 January 2024.

Key Points: 
  • Rebellion Defense is thrilled to announce the appointment of Executive Chair Ben FitzGerald as its new Chief Executive Officer (CEO), effective 1 January 2024.
  • FitzGerald will replace Interim CEO Barry Sowerine, who will join the company’s Board of Directors (the “Board”).
  • View the full release here: https://www.businesswire.com/news/home/20231218858710/en/
    Ben FitzGerald, Executive Chair and incoming CEO at Rebellion Defense.
  • Rebellion Defense, with its new leadership, is poised for innovation and growth, continuing to make significant contributions to 21st-century defense missions.

Ping-pong diplomacy: Australian table tennis players return to China, five decades after historic tour

Retrieved on: 
Friday, October 27, 2023

Only weeks after the team’s headline-making tour, Australia’s then opposition leader, Gough Whitlam, led a delegation to Beijing promising to open diplomatic relations “when elected”.

Key Points: 
  • Only weeks after the team’s headline-making tour, Australia’s then opposition leader, Gough Whitlam, led a delegation to Beijing promising to open diplomatic relations “when elected”.
  • One was table tennis, one was basketball and one was volleyball.
  • One was table tennis, one was basketball and one was volleyball.

‘A crowd of 8,000 people’

  • A revolutionary who became one of China’s most revered statesmen, he advocated peaceful co-existence with the West and other nations.
  • The American team embarked on their tour first – setting the stage for then-President Richard Nixon’s famous visit to Beijing in 1972.
  • Paul Pinkewich had just turned 20 at the time of the visit, teammate Steve Knapp was only 18.
  • Our first match in Canton, now Guangzhou, I think it was a crowd of 8,000 people,” he recalls.
  • “Do you wear this hair because of your disagreement with society or because it is a style?” Knapp replied, “It is the fashion.”
  • “Can you believe, one table in the middle of the Capital Stadium [in Beijing] with 18,000 spectators, and that was just an amazing experience.
  • But they always let the woman win.” That woman was Anne Middleton, the other player on the 1971 tour, who has since passed away.
  • After the trip we were labelled as communists […] but we were interested in friendship first, competition second.”

Why sport diplomacy matters

  • Beijing has continued to use sport as a diplomatic tool, including becoming the first city in the world to host both a summer and winter Olympic Games (Beijing in 2008 and 2022).
  • French educator Baron Pierre de Coubertin founded the International Olympic Committee in 1894, believing Olympics were a global event.
  • A new term has also emerged in recent years – almost always applied by researchers in democratic nations – to describe undemocratic nations’ forays into global sport: sportswashing.
  • “Amity between people holds the key to sound relations between countries.” At the heart of such amity, sport continues to play a significant role.


Tracey Holmes was one of the fifty Australians interviewed in the 'Fifty People, Fifty Stories' book due to her experiences of previously living and working in China.

Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Retrieved on: 
Thursday, December 8, 2022

HZN-457 is a small interfering RNA (siRNA) candidate designed to treat gout by silencing liver xanthine dehydrogenase.

Key Points: 
  • HZN-457 is a small interfering RNA (siRNA) candidate designed to treat gout by silencing liver xanthine dehydrogenase.
  • The HZN-457 Phase 1 clinical trial marks an important milestone for Horizon to advance our research and development in this space, fostered by our partnership with Arrowhead.
  • Gout is a serious and painful form of inflammatory arthritis that is caused by excess uric acid.
  • Approximately 56 healthy volunteers are expected to be enrolled sequentially into ascending dose cohorts and administered HZN-457 subcutaneously as a single dose.

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Retrieved on: 
Thursday, December 8, 2022

HZN-457 is a small interfering RNA (siRNA) candidate designed to treat gout by silencing liver xanthine dehydrogenase.

Key Points: 
  • HZN-457 is a small interfering RNA (siRNA) candidate designed to treat gout by silencing liver xanthine dehydrogenase.
  • Gout is a serious and painful form of inflammatory arthritis that is caused by excess uric acid.
  • Secondary endpoints include the assessment of plasma and urine pharmacokinetic parameters and changes from baseline in uric acid levels.
  • The HZN-457 Phase 1 clinical trial marks an important milestone for Horizon to advance our research and development in this space, fostered by our partnership with Arrowhead.

Tremeau Receives May Proceed Notification From FDA For Phase III Program in Acute Migraine For TRM-201 (Rofecoxib)

Retrieved on: 
Tuesday, June 14, 2022

Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.

Key Points: 
  • Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.
  • Previously marketed as VIOXX, rofecoxib is a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID) with a well-established efficacy profile in multiple indications, including acute migraine.
  • Tremeau expects that the development program for TRM-201 will include one Phase III acute efficacy and safety study in migraine.
  • Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.

Overseas Adventure Travel Shares Top 4 Travel Trends for 2022

Retrieved on: 
Monday, January 10, 2022

BOSTON, Jan. 10, 2022 /PRNewswire/ --2022 may be the year that travel really comes back.

Key Points: 
  • BOSTON, Jan. 10, 2022 /PRNewswire/ --2022 may be the year that travel really comes back.
  • Overseas Adventure Travel (O.A.T.)
  • , the leader in personalized small group and solo-friendly travel for Americans ages 50+,announced its top 4 travel themes for the year ahead.
  • resumed travel in July 2021 and brought 11,000 travelers to more than 30 countries.In 2022, nearly 69,000 travelers have reserved travel with O.A.T., which typically offers travel to 85 countries.

Tremeau Expands Pipeline with Novel Non-Opioid Compound for the Treatment of Acute Pain

Retrieved on: 
Monday, October 25, 2021

Once issued, the patent will provide composition of matter patent protection for Tremeaus novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.

Key Points: 
  • Once issued, the patent will provide composition of matter patent protection for Tremeaus novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.
  • These studies suggest that TRM-362 could provide similar or greater acute pain efficacy when compared to non-enriched etoricoxib, potentially at a lower dose.
  • The surgical community would welcome a more potent non-opioid pain medication that does not carry the bleeding risk of traditional NSAIDs.
  • We will work proactively with FDA to design a product for acute pain that ensures access only for short-term use.